NDATOPICALCREAM
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
OXISTAT (oxiconazole nitrate) by Sandoz is clinical pharmacology pharmacokinetics: the penetration of oxiconazole nitrate into different layers of the skin was assessed using an in vitro permeation technique with human skin. First approved in 1988.
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXISTAT (oxiconazole nitrate) is a topical imidazole antifungal cream approved in 1988 for treating dermatophyte and yeast infections of the skin. It works by inhibiting ergosterol biosynthesis in fungal cell membranes, disrupting cellular integrity. The drug has low systemic absorption (<0.3% urinary recovery) and concentrates in epidermal layers where fungal infections occur.
$0.251MPart D
LOE ApproachingDeclining
Minimal Medicare D activity and declining claims indicate this is a mature, low-volume product with limited team expansion opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics: The penetration of oxiconazole nitrate into different layers of the skin was assessed using an in vitro permeation technique with human skin. Five hours after application of 2.5 mg/cm of oxiconazole nitrate cream onto human skin, the concentration of…
Indications
Worked on OXISTAT at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.